Clinical trials
Phase 3 Amyloidosis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
35 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 7 |
| Not yet recruiting | 3 |
| Active, not recruiting | 3 |
| Enrolling by invitation | 2 |
| Terminated | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alnylam Pharmaceuticals | 7 |
| Eidos Therapeutics, a BridgeBio company | 5 |
| Ionis Pharmaceuticals, Inc. | 4 |
| Pfizer | 3 |
| Brigham and Women's Hospital | 2 |
| Intellia Therapeutics | 2 |
| AbbVie | 1 |
| Alexion Pharmaceuticals, Inc. | 1 |
| C.T. Development America, Inc. | 1 |
| European Myeloma Network B.V. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Amyloidosis | 35 |
| Amyloid Neuropathies, Familial | 14 |
| Cardiomyopathies | 10 |
| Alzheimer Disease | 7 |
| Amyloidosis, Familial | 7 |
| Polyneuropathies | 7 |
| Immunoglobulin Light-chain Amyloidosis | 4 |
| Heart Diseases | 3 |
| Amyloid Neuropathies | 2 |
| Disease | 2 |
Trials
Showing 1 to 25 of 35. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.